Sci Signal:治疗小儿哮喘患者的新靶点

2018-03-19 药明康德 学术经纬

2型辅助性T细胞 (T helper 2, TH2) 不但在媒介人体对外来寄生虫的免疫反应中有重要所用,而且也会促进包括哮喘在内的过敏性疾病的发生。

2型辅助性T细胞 (T helper 2, TH2) 不但在媒介人体对外来寄生虫的免疫反应中有重要所用,而且也会促进包括哮喘在内的过敏性疾病的发生。辛辛那提儿童医院医疗中心 (Cincinnati Children’s Hospital Medical Center) 的研究人员发现,由上皮细胞和先天免疫细胞分泌的胸腺基质淋巴细胞生成素 (thymic stromal lymphopoietin, TSLP) 能够刺激TH2细胞的致病反应。在小鼠CD4阳性T细胞中, TSLP信号通路会启动向TH2细胞分化的转录程序。而且,在TSLP和IL4细胞因子共同刺激下分化出的TH2细胞能够分泌更多的IL-5, IL-13 和其它促进炎症的细胞因子,因而致病能力更强。由于在小儿哮喘患者中TH2细胞生成的细胞因子与健康儿童相比显着提高。这项研究意味着TSLP可能成为治疗这类过敏疾病的靶点。

原始出处:

Yrina Rochman,et al.TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state.Sci Signal.13 Mar 2018:Vol. 11, Issue 521, eaam8858.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036175, encodeId=bcb220361e5dd, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Apr 10 21:33:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793997, encodeId=d3ea1e939976f, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Dec 06 21:33:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288253, encodeId=54d31288253d9, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 21 04:33:00 CST 2018, time=2018-03-21, status=1, ipAttribution=)]
    2018-04-10 楚秀娟
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036175, encodeId=bcb220361e5dd, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Apr 10 21:33:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793997, encodeId=d3ea1e939976f, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Dec 06 21:33:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288253, encodeId=54d31288253d9, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 21 04:33:00 CST 2018, time=2018-03-21, status=1, ipAttribution=)]
    2018-12-06 yaanren
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036175, encodeId=bcb220361e5dd, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Apr 10 21:33:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793997, encodeId=d3ea1e939976f, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu Dec 06 21:33:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288253, encodeId=54d31288253d9, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 21 04:33:00 CST 2018, time=2018-03-21, status=1, ipAttribution=)]
    2018-03-21 lsndxfj